nach oben

Medical Oncology

Erschienen in:

25.07.2021 | COVID-19 | Review Article Zur Zeit gratis

Cancer and COVID-19: Why are cancer patients more susceptible to COVID-19?

verfasst von: Saptarshi Sinha, Chanakya Nath Kundu

Erschienen in: Medical Oncology | Ausgabe 9/2021

Einloggen, um Zugang zu erhalten

Abstract

The COVID-19 pandemic has engulfed the entire world and has claimed more than 3 million lives worldwide. This viral disease is caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) and mainly characterized by fever, dry cough, fatigue, anosmia, anorexia, and dyspnea. The severity of the disease increases with age and presence of comorbidities, including cancer. Multiple clinical studies have shown that the cancer patients are highly susceptible to the severe form of the viral disease. In this review article, we have summarized the available scientific literature regarding the molecular links between COVID-19 and cancer, which make the cancer patients highly susceptible to COVID-19. Few studies have shown that the angiotensin-converting enzyme 2 (ACE2) receptor, transmembrane protease serine 2 (TMPRSS2), and the immune response and inflammation establish the interconnection between the two diseases. Additionally, we have also discussed whether SARS-CoV-2 can contribute to cancer development in COVID-19 patients. A recent study has suggested that SARS-CoV-2 may create a microenvironment that may support cancer cell proliferation and induce the activation of dormant cancer cells (DCCs). In another study, the blood sera of COVID-19 patients were found to activate epithelial-to-mesenchymal transition (EMT) in cancer cells. Overall, this review article will surely help the scientific community to understand why the cancer patients are so much prone to COVID-19 and will also motivate the researchers to find new therapeutic strategies that may save the lives of many COVID-19-infected cancer patients.

Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020;382(8):727–33. https://doi.org/10.1056/NEJMoa2001017.CrossRefPubMedPubMedCentral

Singhal T. A review of coronavirus disease-2019 (COVID-19). Indian J Pediatr. 2020;87:281–6. https://doi.org/10.1007/s12098-020-03263-6.CrossRefPubMedPubMedCentral

World Health Organization. WHO statement regarding cluster of pneumonia cases in Wuhan, China. 2020. https://www.who.int/china/news/detail/09-01-2020-who-statement-regarding-cluster-of-pneumonia-cases-in-wuhan-china. Accessed 24 Apr 2021.

World Health Organization. WHO coronavirus disease (COVID-19) dashboard. 2020. https://covid19.who.int/. Accessed 06 June 2021.

World Health Organization. Novel coronavirus (2019-nCoV) situation report-11. 2020. https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200131-sitrep-11-ncov.pdf?sfvrsn=de7c0f7_4. Accessed 24 Apr 2021.

World Health Organization. Novel coronavirus (2019-nCoV) situation report-51. 2020. https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200311-sitrep-51-covid-19.pdf?sfvrsn=1ba62e57_10. Accessed 24 Apr 2021.

World Health Organization. COVID-19 weekly operational update on COVID-19. 2021. https://www.who.int/publications/m/item/weekly-operational-update-on-covid-19---14-june-2021. Accessed 21 June 2021.

Hindson J. COVID-19: faecal–oral transmission? Nat Rev Gastroenterol Hepatol. 2020;17:259. https://doi.org/10.1038/s41575-020-0295-7.CrossRefPubMedPubMedCentral

Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497–506. https://doi.org/10.1016/S0140-6736(20)30183-5.CrossRefPubMedPubMedCentral

10.

Tay MZ, Poh CM, Rénia L, MacAry PA, Ng LFP. The trinity of COVID-19: immunity, inflammation and intervention. Nat Rev Immunol. 2020;20:363–74. https://doi.org/10.1038/s41577-020-0311-8.CrossRefPubMed

11.

Dai M, Liu D, Liu M, Zhou F, Li G, Chen Z, et al. Patients with cancer appear more vulnerable to SARS-CoV-2: a multicenter study during the COVID-19 outbreak. Cancer Discov. 2020;10(6):783–91. https://doi.org/10.1158/2159-8290.CD-20-0422.CrossRefPubMedPubMedCentral

12.

Liang W, Guan W, Chen R, Wang W, Li J, Xu K, et al. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. Lancet Oncol. 2020;21(3):335–7. https://doi.org/10.1016/S1470-2045(20)30096-6.CrossRefPubMedPubMedCentral

13.

Desai A, Sachdeva S, Parekh T, Desai R. COVID-19 and cancer: lessons from a pooled meta analysis. JCO Glob Oncol. 2020;6:557–9. https://doi.org/10.1200/GO.20.00097.CrossRefPubMed

14.

Zhang L, Zhu F, Xie L, Wang C, Wang J, Chen R, et al. Clinical characteristics of COVID-19-infected cancer patients: a retrospective case study in three hospitals within Wuhan. China Ann Oncol. 2020;31(7):894–901. https://doi.org/10.1016/j.annonc.2020.03.296.CrossRefPubMed

15.

Mehta V, Goel S, Kabarriti R, Cole D, Goldfinger M, Acuna-Villaorduna A, et al. Case fatality rate of cancer patients with COVID-19 in a New York hospital system. Cancer Discov. 2020;10(7):935–41. https://doi.org/10.1158/2159-8290.CD-20-0516.CrossRefPubMedPubMedCentral

16.

Yu J, Ouyang W, Chua MLK, Xie C. SARS-CoV-2 transmission in patients with cancer at a Tertiary Care Hospital in Wuhan, China. JAMA Oncol. 2020;6(7):1108–10. https://doi.org/10.1001/jamaoncol.2020.0980.CrossRefPubMedPubMedCentral

17.

Bhattacharjee A, Patil VM, Dikshit R, Prabhash K, Singh A, Chaturvedi P. Should we wait or not? The preferable option for patients with stage IV oral cancer in COVID-19 pandemic. Head Neck. 2020;42(6):1173–8. https://doi.org/10.1002/hed.26196.CrossRefPubMedPubMedCentral

18.

Wu F, Zhao S, Yu B, Chen YM, Wang W, Song ZG, et al. A new coronavirus associated with human respiratory disease in China. Nature. 2020;579(7798):265–9. https://doi.org/10.1038/s41586-020-2008-3.CrossRefPubMedPubMedCentral

19.

Sungnak W, Huang N, Bécavin C, Berg M, Queen R, Litvinukova M, et al. SARSCoV-2 entry factors are highly expressed in nasal epithelial cells together with innate immune genes. Nat Med. 2020;26(5):681–7. https://doi.org/10.1038/s41591-020-0868-6.CrossRefPubMedPubMedCentral

20.

Hoffmann M, Kleine-Weber H, Schroeder S, Krüger N, Herrler T, Erichsen S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020;181(2):271-280.e8. https://doi.org/10.1016/j.cell.2020.02.052.CrossRefPubMedPubMedCentral

21.

Walls AC, Park YJ, Tortorici MA, Wall A, McGuire AT, Veesler D. Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein. Cell. 2020;181(2):281-292.e6. https://doi.org/10.1016/j.cell.2020.02.058.CrossRefPubMedPubMedCentral

22.

Hoffmann M, Kleine-Weber H, Pöhlmann S. A multibasic cleavage site in the spike protein of SARS-CoV-2 is essential for infection of human lung cells. Mol Cell. 2020;78(4):779-784.e5. https://doi.org/10.1016/j.molcel.2020.04.022.CrossRefPubMedPubMedCentral

23.

Bao L, Deng W, Huang B, Gao H, Liu J, Ren L, et al. The pathogenicity of SARS-CoV-2 in hACE2 transgenic mice. Nature. 2020;583:830–3. https://doi.org/10.1038/s41586-020-2312-y.CrossRefPubMed

24.

Muus C, Luecken M, Eraslan G, Waghray A, Heimberg G, Sikkema L, et al. Integrated analyses of single-cell atlases reveal age, gender, and smoking status associations with cell type-specific expression of mediators of SARS-CoV-2 viral entry and highlights inflammatory programs in putative target cells. BioRxiv. 2020. https://doi.org/10.1101/2020.04.19.049254.CrossRef

25.

Sidaway P. COVID-19 and cancer: what we know so far. Nat Rev Clin Oncol. 2020;17(6):336. https://doi.org/10.1038/s41571-020-0366-2.CrossRefPubMed

26.

National Cancer Institute. Age and cancer risk. https://www.cancer.gov/about-cancer/causes-prevention/risk/age. 2021. Accessed 25 May 2021.

27.

Pinto BG, Oliveira AE, Singh Y, Jimenez L, Gonçalves AN, Ogava RL, et al. ACE2 expression is increased in the lungs of patients with comorbidities associated with severe COVID-19. J Infect Dis. 2020;222(4):556–63. https://doi.org/10.1093/infdis/jiaa332.CrossRefPubMed

28.

Smith JC, Sausville EL, Girish V, Yuan ML, Vasudevan A, John KM, et al. Cigarette smoke exposure and inflammatory signaling increase the expression of the SARS-CoV-2 receptor ACE2 in the respiratory tract. Dev Cell. 2020;53(5):514–29. https://doi.org/10.1016/j.devcel.2020.05.012.CrossRefPubMedPubMedCentral

29.

Stopsack KH, Mucci LA, Antonarakis ES, Nelson PS, Kantoff PW. TMPRSS2 and COVID-19: serendipity or opportunity for intervention? Cancer Discov. 2020;10(6):779–82. https://doi.org/10.1158/2159-8290.CD-20-0451.CrossRefPubMedPubMedCentral

30.

Montopoli M, Zumerle S, Vettor R, Rugge M, Zorzi M, Catapano CV, et al. Androgen-deprivation therapies for prostate cancer and risk of infection by SARS-CoV-2: a population-based study (n= 4532). Ann Oncol. 2020;31(8):1040–5. https://doi.org/10.1016/j.annonc.2020.04.479.CrossRefPubMed

31.

Patel VG, Zhong X, Liaw B, Tremblay D, Tsao CK, Galsky MD, et al. Does androgen deprivation therapy protect against severe complications from COVID-19? Ann Oncol. 2020;31(10):1419–20. https://doi.org/10.1016/j.annonc.2020.06.023.CrossRefPubMed

32.

Saini KS, de las Heras B, de Castro J, et al. Effect of the COVID-19 pandemic on cancer treatment and research. Lancet Haematol. 2020;7(6):e432–5. https://doi.org/10.1016/S2352-3026(20)30123-X.CrossRefPubMedPubMedCentral

33.

Sica A, Colombo MP, Trama A, Horn L, Garassino MC, Torri V. Immunometabolic status of COVID-19 cancer patients. Physiol Rev. 2020;100(4):1839–50. https://doi.org/10.1152/physrev.00018.2020.CrossRefPubMedPubMedCentral

34.

Merad M, Martin JC. Pathological inflammation in patients with COVID-19: a key role for monocytes and macrophages. Nat Rev Immunol. 2020;20:355–62. https://doi.org/10.1038/s41577-020-0331-4.CrossRefPubMedPubMedCentral

35.

Moore JB, June CH. Cytokine release syndrome in severe COVID-19. Science. 2020;368(6490):473–4. https://doi.org/10.1126/science.abb8925.CrossRefPubMed

36.

Bakouny Z, Hawley JE, Choueiri TK, Peters S, Rini BI, Warner JL. COVID-19 and cancer: current challenges and perspectives. Cancer Cell. 2020;38(5):629–46. https://doi.org/10.1016/j.ccell.2020.09.018.CrossRefPubMedPubMedCentral

37.

McGonagle D, O’Donnell JS, Sharif K, Emery P, Bridgewood C. Immune mechanisms of pulmonary intravascular coagulopathy in COVID-19 pneumonia. Lancet Rheumatol. 2020;2(7):e437–45. https://doi.org/10.1016/S2665-9913(20)30121-1.CrossRefPubMedPubMedCentral

38.

Jose RJ, Manuel A. COVID-19 cytokine storm: the interplay between inflammation and coagulation. Lancet Respir Med. 2020;8(6):e46–7. https://doi.org/10.1016/S2213-2600(20)30216-2.CrossRefPubMed

39.

Moll M, Zon RL, Sylvester KW, Chen EC, Cheng V, Connell NT, et al. VTE in ICU patients with COVID-19. Chest. 2020;158(5):2130–5. https://doi.org/10.1016/j.chest.2020.07.031.CrossRefPubMed

40.

Geisslinger F, Vollmar AM, Bartel K. Cancer patients have a higher risk regarding COVID-19—and vice versa? Pharmaceuticals (Basel). 2020;13(7):143. https://doi.org/10.3390/ph13070143.CrossRef

41.

Bhardwaj K, Liu P, Leibowitz JL, Kao CC. The coronavirus endoribonuclease Nsp15 interacts with retinoblastoma tumor suppressor protein. J Virol. 2012;86(8):4294–304. https://doi.org/10.1128/JVI.07012-11.CrossRefPubMedPubMedCentral

42.

Han HJ, Nwagwu C, Anyim O, Ekweremadu C, Kim S. COVID-19 and cancer: from basic mechanisms to vaccine development using nanotechnology. Int Immunopharmacol. 2021;90: 107247. https://doi.org/10.1016/j.intimp.2020.107247.CrossRefPubMed

43.

Venkataraman T, Coleman C, Frieman MB. Overactive epidermal growth factor receptor signaling leads to increased fibrosis after severe acute respiratory syndrome coronavirus infection. J Virol. 2017;91:e00182-e217. https://doi.org/10.1128/JVI.00182-17.CrossRefPubMedPubMedCentral

44.

Piersma B, Hayward MK, Weaver VM. Fibrosis and cancer: a strained relationship. Biochim Biophys Acta Rev Cancer. 2020;1873(2):188356. https://doi.org/10.1016/j.bbcan.2020.188356.CrossRefPubMedPubMedCentral

45.

Francescangeli F, De Angelis ML, Baiocchi M, Rossi R, Biffoni M, Zeuner A. COVID-19–induced modifications in the tumor microenvironment: do they affect cancer reawakening and metastatic relapse? Front Oncol. 2020;10:592891. https://doi.org/10.3389/fonc.2020.592891.CrossRefPubMedPubMedCentral

46.

Francescangeli F, De Angelis ML, Zeuner A. COVID-19: a potential driver of immune-mediated breast cancer recurrence? Breast Cancer Res. 2020;22:117. https://doi.org/10.1186/s13058-020-01360-0.CrossRefPubMedPubMedCentral

47.

Stewart CA, Gay CM, Ramkumar K, Cargill KR, Cardnell RJ, Nilsson MB, et al. Lung cancer models reveal SARS-CoV-2-induced EMT contributes to COVID-19 pathophysiology. bioRxiv. 2020. https://doi.org/10.1101/2020.05.28.122291.CrossRefPubMedPubMedCentral

48.

Saygideger Y, Sezan A, Candevir A, Demir BS, Guzel E, Baydar O, et al. COVID-19 patients’ sera induce epithelial mesenchymal transition in cancer cells. Cancer Treat Res Commun. 2021;28:100406. https://doi.org/10.1016/j.ctarc.2021.100406.CrossRefPubMedPubMedCentral

49.

Abid MB, Mughal M, Abid MA. Coronavirus disease 2019 (COVID-19) and immune-engaging cancer treatment. JAMA Oncol. 2020;6(10):1529–30. https://doi.org/10.1001/jamaoncol.2020.2367.CrossRefPubMed

50.

Nagar H, Formenti SC. Cancer and COVID-19—potentially deleterious effects of delaying radiotherapy. Nat Rev Clin Oncol. 2020;17:332–4. https://doi.org/10.1038/s41571-020-0375-1.CrossRefPubMedPubMedCentral

51.

Spicer J, Chamberlain C, Papa S. Provision of cancer care during the COVID-19 pandemic. Nat Rev Clin Oncol. 2020;17:329–31. https://doi.org/10.1038/s41571-020-0370-6.CrossRefPubMedPubMedCentral

Titel: Cancer and COVID-19: Why are cancer patients more susceptible to COVID-19?
verfasst von: Saptarshi Sinha
Chanakya Nath Kundu
Publikationsdatum: 25.07.2021
Verlag: Springer US
Schlagwörter: COVID-19
Onkologie und Hämatologie
Erschienen in: Medical Oncology / Ausgabe 9/2021
Print ISSN: 1357-0560
Elektronische ISSN: 1559-131X
DOI: https://doi.org/10.1007/s12032-021-01553-3

Klimawandel und Gesundheit: Was Sie in der Hausarztpraxis wissen müssen und tun können

Springer Medizin

Cancer and COVID-19: Why are cancer patients more susceptible to COVID-19?

Abstract

Neu im Fachgebiet Onkologie

Viel pflanzliche Nahrung, seltener Prostata-Ca.-Progression

Alter verschlechtert Prognose bei Endometriumkarzinom

Darf man die Behandlung eines Neonazis ablehnen?

Erhöhte Mortalität bei postpartalem Brustkrebs

Update Onkologie

Klimawandel und Gesundheit: Was Sie in der Hausarztpraxis wissen müssen und tun können

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 9/2021

Combined evaluation of proliferation and apoptosis to calculate IC50 of VPA-induced PANC-1 cells and assessing its effect on the Wnt signaling pathway

Combinatorial treatment with Gefitinib and Bay11-7085 sensitizes primary Gefitinib-resistant OSCC cells by influencing the EGFR- NFκB signaling axis

Phase II study of neoadjuvant chemotherapy with S-1 plus oxaliplatin for gastric cancer clinical T4 or N2-3

Employing bioinformatics analysis to identify hub genes and microRNAs involved in colorectal cancer

MPI-based bioinformatic analysis and co-inhibitory therapy with mannose for oral squamous cell carcinoma

Hypofractionated whole-breast radiotherapy in large breast size patients: is it really a resolved issue?

Neu im Fachgebiet Onkologie

Viel pflanzliche Nahrung, seltener Prostata-Ca.-Progression

Alter verschlechtert Prognose bei Endometriumkarzinom

Darf man die Behandlung eines Neonazis ablehnen?

Erhöhte Mortalität bei postpartalem Brustkrebs

Update Onkologie